Polycystic ovary syndrome: implications of metabolic dysfunction

Ávila, Márcio Augusto Pinto de; Bruno, Ricardo Vasconcellos; Barbosa, Fabio Cuiabano; Andrade, Felipe Cupertino de; Silva, Adriana Cardoso de Oliveira e; Nardi, Antônio Egídio

doi:10.1590/s0100-69912014000200006

Cited by 9 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The two studies from Venezuela ( 62 , 63 ) used criteria defined by the authors. Sixteen studies had no control group for comparison ( 24 , 26 , 27 , 35 , 38 , 39 , 43 – 45 , 47 , 51 , 53 , 57 , 59 , 63 ), and six had BMI-matched controls without PCOS for comparison ( 28 , 29 , 34 , 40 , 50 , 55 ). NOS score was 7-9 in 33 studies and ≤ 6 in 7 ( Table 2 ).…”

Section: Resultsmentioning

confidence: 99%

Metabolic Features of Women With Polycystic Ovary Syndrome in Latin America: A Systematic Review

2021

View full text Add to dashboard Cite

BackgroundPolycystic ovary syndrome (PCOS) is an endocrine disorder that commonly affects women of childbearing age and has been associated with metabolic and reproductive abnormalities. Only a few studies have investigated metabolic traits in women with PCOS in Latin America. Therefore, we conducted a systematic review to provide an overview of the available evidence on the metabolic profile of Latin American women with PCOS.MethodsWe searched PubMed, Cochrane Central Register of Controlled Trials, and Embase databases for cross-sectional, case-control, or cohort studies focusing on populations of countries in South and Central America and Mexico, published until October 31, 2019. We selected studies that reported the diagnostic criteria for PCOS. In the absence of a control group, we included studies if they reported relevant metabolic data.ResultsThe initial search yielded 4878 records, of which 41 studies were included in the systematic review. Sample sizes ranged from 10 to 288 in PCOS groups and from 10 to 1500 in control groups. The prevalence of phenotypes A and B (classic PCOS) ranged from 65.8% to 87.5% as reported in studies from Argentina, Brazil, and Chile. Metabolic syndrome ranged from 33.3% to 44.0% for phenotype A, from 15.0% to 58.0% for phenotype B, from 11.9% to 36.0% for phenotype C, and from 14.2% to 66.0% for phenotype D. Women with PCOS had higher body mass index, waist circumference, blood pressure, glucose, and homeostasis model assessment index as well as a more adverse lipid profile than those without PCOS.ConclusionsEvidence from the present systematic review suggests that anthropometric and metabolic profiles are worse in women with PCOS who live in different Latin American countries than in women without PCOS living in the same region. Additional studies assessing metabolic comorbidities, such as diabetes, and distinct PCOS phenotypes in different Latin American countries are warranted and may produce invaluable information for primary and secondary prevention of PCOS in the region. This systematic review was registered with PROSPERO under number CRD42016038537.Systematic Review RegistrationPROSPERO, identifier CRD42016038537.

show abstract

Section: Resultsmentioning

confidence: 99%

Metabolic Features of Women With Polycystic Ovary Syndrome in Latin America: A Systematic Review

2021

View full text Add to dashboard Cite

show abstract

“…Effect on the glycemic profile. As already discussed, the PCOS pathogenesis may have a direct link to insulin resistance since hyperinsulinemia promotes hyperandrogenism by stimulating androgen synthesis via teak cells and reduces SHBG and thus, produces free testosterone increasingly (Avila et al 2014;Sadeghi et al 2017). Studies have shown that women with PCOS have an increased risk of type 2 diabetes mellitus (DM2) in comparison to non-PCOS women, and more than 50% of patients with PCOS are insulin resistant (Unluhizarci et al 2012;Jamil et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS) – a review of clinical trials and cohort

Thomas

Silva

Freitas

et al. 2022

Endocrine Regulations

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women associated with cardiovascular disease and obesity. The possible benefits of omega-3 supplementation in this syndrome have been discussed much. This study is aimed to verify, based on the scientific data published, if there are any benefits in the omega-3 supplementation in the treatment of PCOS and to indicate its possible dosages for the treatment of polycystic ovary. The work consists of a systematic review of clinical trials and cohort of the MEDLINE/PubMed database from 2009 to October 2019. All studies that analyzed the omega-3 supplementation in women with PCOS were included. Cross-sectional studies, review articles, systematic reviews, meta-analysis, duplicates, studies in animals or cell culture, studies with omega-3 supplementation via food or associated with other supplementations were not included, except those involving vitamin E. In total, 21 articles were selected. Despite the heterogeneity of the studies selected, indirect benefits were observed mainly regarding the glycemic profile, such as insulin resistance reduction, lipid profile modulation (i.e. decrease in total cholesterol, triglycerides, and elevation of high-density lipoprotein), and the regulation of the androgenic profile. As for the anthropometric profile, the studies were scarce and most of them had no significant meaning. Regarding the antioxidant profile and inflammatory biomarkers, the findings differ among studies, but promising results were observed with different doses over 12 weeks of use, such as C-reactive protein (CRP) reduction. Thus, omega-3 fatty acids promote indirect benefits in the treating of women with PCOS. However, to reveal well-defined standards for dosage and supplementation time, further studies are needed.

show abstract

“…Table 1 summarizes the characteristics of studies on Brazilian populations. Seven studies were from the Northeast region [23][24][25][26][27][28][29], thirteen studies were from the Southeast [30][31][32][33][34][35][36][37][38][39][40][41][42], five studies were from the South [43][44][45][46][47], and two studies were from the Midwest region [48,49]. No data from the North region were available.…”

Section: Discussionmentioning

confidence: 99%

Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis

Spritzer

Ramos

Marchesan

et al. 2021

Diabetol Metab Syndr

View full text Add to dashboard Cite

Background Polycystic ovary syndrome (PCOS) is a common endocrine disease affecting women of reproductive age and associated with reproductive and metabolic dysfunction. Few studies are available regarding metabolic traits in Brazilian women with PCOS. The aim of this systematic review and meta-analysis was to summarize the available evidence regarding metabolic traits and comorbidities in Brazilian women with polycystic ovary syndrome (PCOS). Methods We systematically searched PubMed, Cochrane Central Register of Controlled Trials, and Embase for cross-sectional, case–control, or cohort studies focusing on populations of different regions from Brazil, published until July 31, 2019. Studies were selected if they reported PCOS diagnostic criteria. Studies without a control group were included if they presented relevant metabolic data. Results Of 4856 studies initially identified, 27 were included in the systematic review and 12 were included in the meta-analysis, for a total of 995 women with PCOS defined by Rotterdam criteria and 2275 controls from different regions of Brazil. Obesity, metabolic syndrome and IGT were prevalent, and standard mean differences for BMI (SMD 0.67, 95% CI, 0.29, 1.05), waist circumference (SMD 0.22, 95% CI 0.02, 0.41), systolic (SMD 0.66, 95% CI 0.30, 1.01) and diastolic blood pressure (SMD 0.55, 95% CI 0.24, 0.87), glucose (SMD 0.21, 95% CI 0.04, 0.38) and HOMA (SMD 0.78, 95% CI 0.52, 1.04) were significantly higher in Brazilian women with PCOS compared to controls. Lipid profile was more adverse in PCOS vs. non-PCOS women. Between-study heterogeneities were low/moderate for glucose and HOMA and moderate/high for the other variables. Conclusions The data of this systematic review and meta-analysis indicate that Brazilian women with PCOS have a worse metabolic profile than women without PCOS with no important regional differences. The prevalence of metabolic changes is intermediate in Brazil vs. other countries.

show abstract

Polycystic ovary syndrome: implications of metabolic dysfunction

Abstract: We propose the routine inspection of metabolic components related to severe PCOS. These parameters configure the cardiovascular risk and such conduct is of undoubted importance to public health.

Cited by 9 publications

References 30 publications

Metabolic Features of Women With Polycystic Ovary Syndrome in Latin America: A Systematic Review

Metabolic Features of Women With Polycystic Ovary Syndrome in Latin America: A Systematic Review

Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS) – a review of clinical trials and cohort

Metabolic profile of women with PCOS in Brazil: a systematic review and meta-analysis

Contact Info

Product

Resources

About